Patient Selection for Faricimab Treatment in Neovascular AMD

EP: 1.Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapies in Neovascular AMD and DME

EP: 2.Treatment Goals in Neovascular AMD

EP: 3.Phase 3 Studies of Faricimab in Neovascular AMD

EP: 4.Use of Faricimab in Neovascular AMD in Clinical Practice

Now Viewing

EP: 5.Patient Selection for Faricimab Treatment in Neovascular AMD

EP: 6.Safety of Faricimab in Neovascular AMD

EP: 7.Loading Dose Recommendations of Faricimab in Neovascular AMD

EP: 8.Biomarkers of Disease at Baseline in Neovascular AMD

EP: 9.Challenges in DME Management

EP: 10.Key Outcomes of Trials of Faricimab in DME

EP: 11.The YOSEMITE and RHINE Trials in DME

EP: 12.Use of Intraocular Steroids in DME

EP: 13.Faricimab Loading Dose Adherence in DME Therapy

EP: 14.Emerging Therapies in Neovascular AMD and DME

EP: 15.New Therapies to Supplement Anti-VEGF Treatments in Neovascular AMD and DME

EP: 16.Gene Therapy in Neovascular AMD and DME

EP: 17.Approaches to Step Therapy in Neovascular AMD and DME

EP: 18.Role of Biosimilars in Neovascular AMD and DME Treatment

EP: 19.Managing Concurrent Neovascular AMD and Geographic Atrophy (GA)

EP: 20.Key Takeaways on Managing Neovascular AMD and DME

EP: 21.Poll: Exploring the dosing intervals of faricimab for treating neovascular AMD in the clinical practice setting

EP: 22.Poll: What are the biggest challenges in DME Management?

EP: 23.Neovascular AMD and DME therapies: 5 quotes from retina specialists

EP: 24.Poll: Most anticipated emerging therapies in neovascular AMD and DME

Nathan Steinle, MD: Talk me through your patient selection for faricimab.

Adrienne Scott, MD: When aflibercept first became available to us, we thought this was particularly groundbreaking in the fact that it’s an anti-VEGF therapy that could last up to 8 weeks in those patients. I feel like we learned fairly quickly that not all patients could go the 8-week interval, as we saw in the clinical trial. Therefore, we had to start treating people as frequently as every 4 weeks, or 5 or 6 weeks. So, there are a proportion of patients who can’t go 8 weeks with a dry retina and neovascular AMD [age-related macular degeneration], and a certain proportion of patients who have bilateral disease.

For the patients I’m considering switching and for whom I have switched, I speak with them about the potential dual mechanism, but also there are patients who have what we consider a high treatment burden. In my opinion, and that may vary depending on which retina specialist you ask, but a high treatment burden to me is a patient who has to be treated every 4 to 6 weeks, or less than every 8 weeks, oftentimes bilaterally, and their retina still has evidence of agitation or fluid that we don’t want to tolerate. Those are the people I start talking to about, maybe we’ll switch you over to this longer-acting agent.

Nathan Steinle, MD: Do you have any studies that guide us at all, any evidence? I know there’s the TRUCKEE study ongoing, any thoughts about that study?

Adrienne Scott, MD: Yes, I love the TRUCKEE Study. To Dr Regillo’s point, some of these real-world studies do tell us a lot about the behavior of these molecules and the real setting outside of the clinical trial. So I do feel like we’re able to extend more and more, whatever the trials tell us to do as far as the regimen, we’re going to push it. We’re going to add more and more to the extension period. To me in my hands, I’m still learning about the durability of faricimab in certain patients. I am still impressed at the variability of patients and how they respond to the different agents, so I’m still working that out in my hands.

Nathan Steinle, MD: I’ll throw it back to you guys, to the switchers. Have you been switching patients over to faricimab? What’s been your early experience so far?

Prethy Rao, MD, MPH: I think for me, most of what I’ve been using faricimab for are the switchers. I don’t know about you guys, but I feel like faricimab is almost like a fine wine, and I think the trials support it. After the 1-year period, the differences in their drying effects and their visual outcomes become larger and larger, and I feel like maybe that’s more of the Ang-2 [angiopoietin-2] effect. So when I do switch patients, I don’t go back to the every 4-week mark. I stay at that whatever extended period they are, and I stay on that for a few visits. I’ve noticed that while I might not get a great response initially, if I stick with the medication at that interval, over time they respond better. I try to give it a bit more of a chance rather than they switch once, then it doesn’t work, and they have to switch back to the other drug they were on.

Carl Regillo, MD, FACS, FASRS: I’ve had a good experience, and I definitely see the added durability in switching patients, and these are the hardest to treat patients, right? They are patients who are coming and getting injections to get adequate disease control, and usually, it’s adequate disease control. Sometimes it’s suboptimal, but they have high needs every 4, 5, or 6 weeks. Yes, those are the first patients I’m switching, and I’m seeing them in at least another week or two. I don’t expect to go from every 4 weeks for aflibercept to every 12 weeks or even 16 weeks for faricimab. That’s unrealistic because even faricimab will sometimes need to be administered frequently to keep the disease under control. In fact, that’s why its label is every 4 to 16 weeks, but the vast majority of course will be well beyond that if you take all comers with neovascular AMD.

Transcript edited for clarity